Update shared on 01 Nov 2025
Fair value Increased 12%Analysts have raised their price target for NeoGenomics from $10.44 to $11.72 per share. They cite marginal improvements in projected revenue growth and profit margin estimates.
What's in the News
- NeoGenomics will present new research at the ISLB Annual Congress 2025, demonstrating high concordance between RaDaR ST and RaDaR 1.0 assays for molecular residual disease detection in solid tumors (Key Developments)
- The company will showcase progress of its NextGen whole genome-based MRD research program, with multiple posters on liquid biopsy and genomic profiling across solid tumor types (Key Developments)
- The company reaffirmed 2025 earnings guidance with expected consolidated revenue between $720 million and $726 million and a projected net loss between $116 million and $108 million (Key Developments)
- NeoGenomics plans to highlight its MRD assay and oncology research capabilities at the ESMO Congress 2025, emphasizing the role in accelerating oncology drug development (Key Developments)
- A recent legal ruling invalidated certain Natera patent claims against NeoGenomics’ RaDaR test, though the injunction over a separate patent remains in effect (Key Developments)
Valuation Changes
- Consensus Analyst Price Target has risen from $10.44 to $11.72 per share.
- Discount Rate remains unchanged at 6.78%.
- Revenue Growth projections increased slightly, moving from 9.65% to 9.67%.
- Net Profit Margin estimates have risen modestly, from 5.38% to 5.46%.
- Future P/E ratio is up from 34.08x to 36.90x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.